Synektik S.A. - Asset Resilience Ratio

Latest as of September 2025: 0.00%

Synektik S.A. (SNT) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

zł1.31K
≈ $361.87 USD Cash + Short-term Investments

Total Assets

zł489.11 Million
≈ $134.61 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2012–2025)

This chart shows how Synektik S.A.'s Asset Resilience Ratio has changed over time. Check how strategically is Synektik S.A.'s equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Synektik S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SNT market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents zł0.00 0%
Short-term Investments zł1.31K 0.0%
Total Liquid Assets zł1.31K 0.00%

Asset Resilience Insights

  • Limited Liquidity: Synektik S.A. maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Synektik S.A. Industry Peers by Asset Resilience Ratio

Compare Synektik S.A.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Pulsenmore Ltd. Ordinary Shares
NASDAQ:PLSM
Medical Devices 46.67%
Medartis Holding AG
SW:MED
Medical Devices 0.00%
Jafron Biomedical Co Ltd
SHE:300529
Medical Devices 39.15%
HOB Biotech Group Corp Ltd
SHG:688656
Medical Devices 2.62%
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
Medical Devices 34.47%
Universus Photo Imagings Limited
NSE:UNIVPHOTO
Medical Devices 30.97%
Emvision Medical Devices Ltd
AU:EMV
Medical Devices 0.06%
Respiri Ltd
AU:RSH
Medical Devices 0.46%

Annual Asset Resilience Ratio for Synektik S.A. (2012–2025)

The table below shows the annual Asset Resilience Ratio data for Synektik S.A..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.00% zł1.31K
≈ $361.87
zł489.11 Million
≈ $134.61 Million
-0.27pp
2023-12-31 0.27% zł802.49K
≈ $220.86K
zł299.92 Million
≈ $82.54 Million
-0.23pp
2022-12-31 0.50% zł1.18 Million
≈ $324.29K
zł236.48 Million
≈ $65.08 Million
+3.52pp
2021-12-31 -3.02% zł-4.83 Million
≈ $-1.33 Million
zł159.69 Million
≈ $43.95 Million
+1.75pp
2020-12-31 -4.77% zł-6.76 Million
≈ $-1.86 Million
zł141.61 Million
≈ $38.97 Million
-1.32pp
2019-12-31 -3.46% zł-4.33 Million
≈ $-1.19 Million
zł125.10 Million
≈ $34.43 Million
-3.07pp
2018-12-31 -0.39% zł-421.39K
≈ $-115.97K
zł108.59 Million
≈ $29.88 Million
-0.39pp
2016-12-31 0.00% zł-1.50K
≈ $-412.82
zł90.75 Million
≈ $24.98 Million
+0.08pp
2015-12-31 -0.08% zł-85.07K
≈ $-23.41K
zł104.40 Million
≈ $28.73 Million
-0.08pp
2014-12-31 0.00% zł-1.50K
≈ $-412.82
zł106.79 Million
≈ $29.39 Million
-0.83pp
2012-12-31 0.83% zł511.96K
≈ $140.90K
zł61.56 Million
≈ $16.94 Million
--
pp = percentage points

About Synektik S.A.

WAR:SNT Poland Medical Devices
Market Cap
$862.41 Million
zł3.13 Billion PLN
Market Cap Rank
#9390 Global
#47 in Poland
Share Price
zł367.40
Change (1 day)
-1.82%
52-Week Range
zł203.80 - zł394.00
All Time High
zł394.00
About

Synektik Spólka Akcyjna provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland. The company sells medical equipment used in diagnostics and therapy, and nuclear medicine. It is also involved in development of IT solutions used in radiology, as well as research, produces, and sells radiopharmaceutical products used in diagnostics … Read more